SEC Company Response from vTv Therapeutics Inc. (VTVT) (CIK 0001641489) (VTVT) — Jul 11, 2019
vTv Therapeutics Inc. (VTVT) (CIK 0001641489)
Date: July 11, 2019 · CIK: 0001641489 · Accession: 0000950142-19-001547
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232571
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Attention: Tonya Aldave vTv Therapeutics Inc. Registration Statement on Form S‑3 (File No. 333-232571)
Dear Ms. Aldave:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 of vTv Therapeutics Inc. (the “Company”) relating to the registration of 16,448,806 shares of the Company’s Class A common stock, par value $0.01 per share, to be sold by certain selling stockholders named therein, be accelerated to July 15, 2019 at 3:00 p.m. Eastern Time or as soon thereafter as may be practicable.
We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Lawrence G. Wee of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3052.
*****
Very truly yours,
VTV THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm vTv Therapeutics Inc. 4170 Mendenhall Oaks Pkwy High Point, NC 27265 July 11, 2019 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tonya Aldave vTv Therapeutics Inc. Registration Statement on Form S‑3 (File No. 333-232571) Dear Ms. Aldave: Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 of vTv Therapeutics Inc. (the “Company”) relating to the registration of 16,448,806 shares of the Company’s Class A common stock, par value $0.01 per share, to be sold by certain selling stockholders named therein, be accelerated to July 15, 2019 at 3:00 p.m. Eastern Time or as soon thereafter as may be practicable. We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Lawrence G. Wee of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3052. ***** Very truly yours, VTV THERAPEUTICS INC. By: /s/ Rudy Howard Name: Rudy Howard Title: Chief Financial Officer